These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 14966767

  • 1. Implications of recent clinical trials for heart failure performance measures.
    Executive Council Of The Heart Failure Society Of AmericaHeart Failure Society Of America, Court International Suite 240 South, 2550 University Avenue West, St. Paul, MN 55114, USA..
    J Card Fail; 2004 Feb; 10(1):4-5. PubMed ID: 14966767
    [No Abstract] [Full Text] [Related]

  • 2. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
    Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, Benza RL, Gottlieb SO, Kleemann TD, Rosconi F, Vandervoort PM, Cohn JN, Val-HeFT Heart Failure Trial Investigators.
    J Am Coll Cardiol; 2002 Sep 04; 40(5):970-5. PubMed ID: 12225725
    [Abstract] [Full Text] [Related]

  • 3. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Hollenberg NK.
    Curr Hypertens Rep; 2002 Dec 04; 4(6):411; discussion 412. PubMed ID: 12462208
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure.
    Cohn JN.
    Am J Cardiol; 2002 Nov 01; 90(9):992-3. PubMed ID: 12398968
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 01; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 8. VALIANT and EUROPA.
    Liebson PR.
    Prev Cardiol; 2004 Oct 01; 7(1):42-4. PubMed ID: 15010627
    [No Abstract] [Full Text] [Related]

  • 9. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
    Jorde UP, Ennezat PV, Lisker J, Suryadevara V, Infeld J, Cukon S, Hammer A, Sonnenblick EH, Le Jemtel TH.
    Circulation; 2000 Feb 29; 101(8):844-6. PubMed ID: 10694521
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?
    Swedberg K, McMurray JJ.
    Eur Heart J; 2004 Mar 29; 25(5):357-8. PubMed ID: 15033244
    [No Abstract] [Full Text] [Related]

  • 11. Angiotensin-II receptor antagonists: their place in therapy.
    Kirk JK.
    Am Fam Physician; 1999 Jun 29; 59(11):3140-8. PubMed ID: 10392595
    [Abstract] [Full Text] [Related]

  • 12. Are angiotensin II receptor blockers indicated in chronic heart failure?
    Komajda M.
    Heart; 2002 Jan 29; 87(1):1-2. PubMed ID: 11751648
    [No Abstract] [Full Text] [Related]

  • 13. [Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
    Rakugi H, Ogihara T.
    Nihon Rinsho; 2001 Oct 29; 59(10):2051-61. PubMed ID: 11676153
    [Abstract] [Full Text] [Related]

  • 14. [Organ protection by angiotensin II receptor blockers].
    Kumagai H, Onami T, Takimoto C, Iigaya K, Saruta T.
    Nihon Rinsho; 2004 Mar 29; 62 Suppl 3():569-73. PubMed ID: 15171437
    [No Abstract] [Full Text] [Related]

  • 15. Valsartan in heart failure patients previously untreated with an ACE inhibitor.
    Mazayev VP, Fomina IG, Kazakov EN, Sulimov VA, Zvereva TV, Lyusov VA, Orlov VA, Olbinskaya LI, Bolshakova TD, Sullivan J, Spormann DO.
    Int J Cardiol; 1998 Aug 29; 65(3):239-46. PubMed ID: 9740480
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
    Miller AB, Srivastava P.
    Cardiol Clin; 2001 May 29; 19(2):195-202, v. PubMed ID: 11407105
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Are angiotensin II receptor antagonists indicated in chronic heart failure?
    Komajda M.
    Heart Fail Monit; 2002 May 29; 2(3):85-7. PubMed ID: 12634889
    [Abstract] [Full Text] [Related]

  • 19. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)].
    Skvortsov AA, Nasonova SN, Sychev AV, Arbolishvili GN, Baklanova NA, Mareev VIu, Belenkov IuN.
    Ter Arkh; 2005 May 29; 77(8):34-43. PubMed ID: 16206603
    [Abstract] [Full Text] [Related]

  • 20. Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction.
    McMurray JJ.
    Heart; 2001 Jul 29; 86(1):97-103. PubMed ID: 11410575
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.